ReviewFrontiers in cell and developmental biology2026
Lysophosphatidylethanolamine (LysoPE) in health and disease: a narrative review of its pathophysiological mechanisms and translational potential as a biomarker.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lysophosphatidylethanolamine (LysoPE) is a key class of lysophospholipid molecules that play important roles in regulating cell membrane structure, signal transduction, and metabolic regulation. This review consolidates current knowledge on LysoPE's molecular mechanisms, including its biosynthesis, membrane dynamics, and signaling via GPCRs, MAPK, and PI3K/AKT pathways. We critically analyze its context-dependent roles across major disease categories. In metabolic diseases, abnormal LysoPE levels are associated with lipid accumulation and insulin resistance. In the nervous system, LysoPE contributes to neuroinflammation while also exerting neurotrophic and protective effects through MAPK signaling. In tumor progression, LysoPE exhibits tissue-specific pro-migratory or inhibitory effects. LysoPE also shows pathological relevance in cardiovascular diseases, infections, and immune abnormalities. Based on disease-specific expression changes, LysoPE has shown promise as a candidate diagnostic biomarker in preliminary studies, with demonstrated value in treatment efficacy evaluation and prognosis prediction. However, large-scale prospective validation is required before clinical application. Future research should integrate multi-omics technologies and clinical validation to further elucidate its molecular mechanisms and promote its application in precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.